Arbutus Biopharma Corp - Common Shares, without par value (ABUS)

Historical Holders from Q2 2015 to Q3 2025

Symbol
ABUS on Nasdaq
Type / Class
Equity / Common Shares, without par value
Shares outstanding
193M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
118M
Holdings value
$536M
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
166
Number of buys
70
Number of sells
-70
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arbutus Biopharma Corp - Common Shares, without par value (ABUS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Roivant Sciences Ltd. 20.5% 0% $128M 38.8M 0% Roivant Sciences Ltd. 21 Feb 2025
MORGAN STANLEY 11.4% $70.8M 21.5M Morgan Stanley 31 Dec 2024
Whitefort Capital Management, LP 7% $43.8M 13.3M Whitefort Capital Master Fund, LP 20 Feb 2025
Two Seas Capital LP 5.4% $33.8M 10.4M Two Seas Capital LP 30 Jun 2025

Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 118M $536M +$2.49M $4.54 166
2025 Q2 118M $365M +$19.6M $3.09 162
2025 Q1 112M $390M +$29.5M $3.49 167
2024 Q4 104M $340M +$3.77M $3.27 153
2024 Q3 101M $389M +$15.6M $3.85 143
2024 Q2 96.7M $298M +$40.9M $3.09 129
2024 Q1 83.4M $215M +$11.6M $2.58 118
2023 Q4 78.9M $197M +$10.9M $2.50 110
2023 Q3 70.8M $144M +$8.06M $2.03 96
2023 Q2 66.2M $152M +$7.39M $2.30 109
2023 Q1 62.5M $189M +$26.5M $3.03 120
2022 Q4 54.2M $126M +$17.8M $2.33 110
2022 Q3 46.6M $89.1M -$922K $1.91 121
2022 Q2 35.3K $93.6K -$3.03M $2.18 11
2022 Q1 43.9M $131M +$4.24M $2.98 111
2021 Q4 39.7M $154M +$14.1M $3.89 114
2021 Q3 34.9M $150M +$26.3M $4.29 96
2021 Q2 28.9M $87.6M +$7.8M $3.03 83
2021 Q1 26M $86.5M +$11.9M $3.33 88
2020 Q4 21.9M $77.8M -$4.7M $3.55 72
2020 Q3 24.1M $75.5M +$7.77M $3.13 60
2020 Q2 26.1M $47.6M +$749K $1.82 46
2020 Q1 26.3M $26.5M -$13.1M $1.01 44
2019 Q4 24.3M $67.4M +$11.9M $2.78 51
2019 Q3 19.5M $29.7M -$3.27M $1.53 44
2019 Q2 21.1M $44M -$11.2M $2.08 56
2019 Q1 24.1M $86.2M -$441K $3.58 64
2018 Q4 24.2M $92.6M -$11M $3.83 65
2018 Q3 24M $227M +$34.7M $9.45 86
2018 Q2 20.4M $149M +$19.7M $7.30 67
2018 Q1 18.4M $91.9M -$79.6M $5.00 45
2017 Q4 34.2M $173M +$12.8M $5.05 50
2017 Q3 31.3M $194M -$33.6M $6.20 51
2017 Q2 36.9M $133M +$3.19M $3.60 45
2017 Q1 36.3M $118M +$819K $3.25 50
2016 Q4 36.2M $88.8M +$4.2M $2.45 52
2016 Q3 33.4M $115M +$54.7M $3.44 46
2016 Q2 17.5M $61.1M -$710K $3.48 47
2016 Q1 17.7M $73.1M -$3.36M $4.13 47
2015 Q4 18.4M $81.7M -$100M $4.45 47
2015 Q3 34.9M $212M +$211M $6.09 52
2015 Q2 207K $2.46M +$2.46M $11.86 1